Biomedical equipment

Tender description

The procurement is split into lots as follows: Lot 1: HLA Antibody Detection and Definition Systems; Lot 2: Maintenance of Existing Luminex Systems. Please see Section II.2.4) of each lot for detailed description of the procurement. Histocompatibility and immunogenetics (H&I) is a strategic business function of NHS Blood and Transplant (NHSBT) that provides a portfolio of testing and advice which supports the diagnosis and/ or treatment of a variety of medical conditions in the following clinical areas: — solid organ transplantation and clinical advice for donor selection, — haematopoietic stem cell transplantation and clinical advice for donor selection, — blood transfusion and transfusion reactions (SHOT), — platelet refractoriness and provision of HLA/ HPA selected components, — platelet immunology, — granulocyte immunology, — immunogenetics including diagnostic testing and pharmacogenetics, — haematopoietic stem cell donor registry typing. NHSBT require human leukocyte antigen (HLA) antibody detection and definition systems. This is to ensure compatibility between donors and recipients of HLA selected platelets, haematopoietic stem cells for transplantation and solid organ transplantation (renal, liver and cardiothoracic). We must be able to perform HLA antibody detection and definition in an efficient, timely and cost effective manner to meet the demands and expectations of our customers and the patients we serve. For NHSBT these services are supplied through a national network of 6 laboratories located at Birmingham, Bristol, Colindale, Newcastle, Sheffield and Tooting. However, this tender will also allow the Scottish National Blood Transfusion Service (SNBTS) and Welsh Blood Service (WBS) to utilise this agreement. The procurement is split into lots as follows: Lot 1: HLA Antibody detection and definition systems; Lot 2: Maintenance of existing luminex systems. The award of this framework agreement will be to the most economically advantageous tender on the basis of the criteria set out in the invitation to tender guidance document available on Bravo (ref. NHSBT1249). No business whatsoever is guaranteed under any resulting framework agreement or contract indeed there is no guarantee that any framework agreement or contract will be put in place in relation to this notice. No compensation etc will be paid if a tender or resulting framework agreement is withdrawn for any reason. Bidders should take part in this process only on the basis that they fully understand and accept this position. Histocompatibility and immunogenetics (H&I) is a strategic business function of NHS Blood and Transplant (NHSBT) that provides a portfolio of testing and advice which supports the diagnosis and/ or treatment of a variety of medical conditions in the following clinical areas: — solid organ transplantation and clinical advice for donor selection, — haematopoietic stem cell transplantation and clinical advice for donor selection, — blood transfusion and transfusion reactions (SHOT), — platelet refractoriness and provision of HLA/ HPA selected components, — platelet immunology, — granulocyte immunology, — immunogenetics including diagnostic testing and pharmacogenetics, — haematopoietic stem cell donor registry typing. NHSBT require human leukocyte antigen (HLA) antibody detection and definition systems. This is to ensure compatibility between donors and recipients of HLA selected platelets, haematopoietic stem cells for transplantation and solid organ transplantation (renal, liver and cardiothoracic). We must be able to perform HLA antibody detection and definition in an efficient, timely and cost effective manner to meet the demands and expectations of our customers and the patients we serve. For NHSBT these services are supplied through a national network of 6 laboratories located at Birmingham, Bristol, Colindale, Newcastle, Sheffield and Tooting. However, this tender will also allow the Scottish National Blood Transfusion Service (SNBTS) and Welsh Blood Service (WBS) to utilise this agreement. The procurement is split into lots as follows: Lot 1: HLA Antibody detection and definition systems; Lot 2: Maintenance of existing luminex systems The award of this framework agreement will be to the most economically advantageous tender on the basis of the criteria set out in the invitation to tender guidance document available on Bravo (ref. NHSBT1249). No business whatsoever is guaranteed under any resulting framework agreement or contract indeed there is no guarantee that any framework agreement or contract will be put in place in relation to this notice. No compensation etc will be paid if a tender or resulting framework agreement is withdrawn for any reason. Bidders should take part in this process only on the basis that they fully understand and accept this position. Pt this position.